Kringle Pharma, Inc.

TSE:4884 Stock Report

Market Cap: JP¥7.3b

Kringle Pharma Management

Management criteria checks 2/4

Kringle Pharma's CEO is Kiichi Adachi, appointed in Dec 2016, has a tenure of 8.08 years. directly owns 1.26% of the company’s shares, worth ¥92.09M. The average tenure of the management team and the board of directors is 2.1 years and 5.1 years respectively.

Key information

Kiichi Adachi

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.1yrs
CEO ownership1.3%
Management average tenure2.1yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Nov 25
We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15
Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02
We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

CEO

Kiichi Adachi (57 yo)

8.1yrs

Tenure

Mr. Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016 and serves as its Director since December 2005 and has been its Chairman. He was Research Scientist of Paradigm G...

Leadership Team

NamePositionTenureCompensationOwnership
Kiichi Adachi
President8.1yrsno data1.26%
¥ 92.1m
Koichi Murakami
Director of Business Administration Dept.no datano datano data
Daichika Hayata
GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director2.1yrsno datano data
Yoshiyuki Kayano
GM of Quality Assurance Department & Director1.1yrsno datano data

2.1yrs

Average Tenure

53yo

Average Age

Experienced Management: 4884's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kiichi Adachi
President19.1yrsno data1.26%
¥ 92.1m
Koichi Murakami
Director of Business Administration Dept.3.1yrsno datano data
Daichika Hayata
GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director2.1yrsno datano data
Yoshiyuki Kayano
GM of Quality Assurance Department & Director1.1yrsno datano data
Kohichiro Yoshino
Independent Outside Director6.1yrsno datano data
Akihiro Tomoyasu
Part Time Director8.1yrsno datano data
Masahiro Motokawa
Audit & Supervisory Board Member6.1yrsno datano data
Yosuke Yamaguchi
Audit & Supervisory Board Member6.1yrsno datano data
Naomi Doi
External Auditor & Supervisory Board Memberless than a yearno datano data
Masato Fukui
Independent Outside Director4.1yrsno datano data

5.1yrs

Average Tenure

52yo

Average Age

Experienced Board: 4884's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 19:01
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kringle Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyoichiro ShigemuraNomura Securities Co. Ltd.